Flexion Therapeutics, Inc. (NASDAQ:FLXN) received a $39.00 price objective from Wells Fargo & Company in a research report issued on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company’s price objective would indicate a potential upside of 30.30% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 target price (up from $34.00) on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Cantor Fitzgerald set a $40.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $35.00 target price (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and an average price target of $33.56.

Flexion Therapeutics (NASDAQ:FLXN) traded up 10.36% on Friday, hitting $29.93. 8,191,561 shares of the stock traded hands. The stock has a 50-day moving average price of $24.45 and a 200 day moving average price of $22.50. The stock’s market cap is $954.92 million. Flexion Therapeutics has a 12-month low of $15.93 and a 12-month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts expect that Flexion Therapeutics will post ($3.74) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Flexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & Company” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/06/flexion-therapeutics-inc-flxn-given-a-39-00-price-target-at-wells-fargo-company.html.

In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of the stock in a transaction dated Friday, September 1st. The stock was bought at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the transaction, the insider now directly owns 5,000 shares in the company, valued at $120,750. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have bought 5,375 shares of company stock valued at $131,575. 15.98% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ardsley Advisory Partners acquired a new position in Flexion Therapeutics during the second quarter valued at approximately $3,338,000. Wasatch Advisors Inc. grew its holdings in Flexion Therapeutics by 58.7% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after purchasing an additional 376,745 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Flexion Therapeutics by 69.4% during the second quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock valued at $842,000 after purchasing an additional 17,066 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in Flexion Therapeutics by 13.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock valued at $1,284,000 after purchasing an additional 7,667 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Flexion Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after purchasing an additional 811 shares during the period. Hedge funds and other institutional investors own 83.26% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.